Jonathan M. Keller

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

Lesley A. Mathews Griner, Rajarshi Guha, Paul Shinn et al. · Proceedings of the National Academy of Sciences · 2014 · 397 citations · Full text

Medicine, Oncology, Pharmacology +14

Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

Garrett W. Rhyasen, Lyndsey Bolanos, Jing Fang et al. · Cancer Cell · 2013 · 201 citations · Full text

Medicine, Molecular Medicine, Pharmacology +7

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

Michele Ceribelli, Priscilla N. Kelly, Arthur L. Shaffer et al. · Proceedings of the National Academy of Sciences · 2014 · 191 citations · Full text

Medicine, Oncology, Pharmacology +16

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma

Dominik Bogen, Jun S. Wei, David O. Azorsa et al. · Oncotarget · 2015 · 70 citations · Full text

Medicine, Cancer Biology, Oncology +17

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer

Duane H. Hamilton, Lesley A. Mathews Griner, Jonathan M. Keller et al. · Clinical Cancer Research · 2016 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17